Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by Zacks Research

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks reports.

Several other equities analysts have also recently issued reports on AMRX. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. UBS Group increased their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. JPMorgan Chase & Co. restated an “overweight” rating and issued a $22.00 price target on shares of Amneal Pharmaceuticals in a research report on Wednesday, August 26th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Finally, Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Amneal Pharmaceuticals Stock Down 2.2%

AMRX opened at $17.05 on Monday. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The company has a market capitalization of $5.44 billion, a PE ratio of 34.80 and a beta of 1.24. The stock’s fifty day moving average is $17.76 and its 200-day moving average is $15.00. Amneal Pharmaceuticals has a one year low of $9.49 and a one year high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, equities analysts predict that Amneal Pharmaceuticals will post 0.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, EVP Jason Daly sold 210,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the sale, the executive vice president directly owned 35,171 shares in the company, valued at approximately $611,975.40. This trade represents a 85.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 413,016 shares of company stock valued at $7,216,567. Corporate insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AMRX. Kemnay Advisory Services Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. Public Employees Retirement System of Ohio bought a new position in shares of Amneal Pharmaceuticals in the second quarter worth about $29,000. Federated Hermes Inc. increased its position in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after buying an additional 2,168 shares during the period. Comerica Bank increased its position in Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares during the period. Finally, Transamerica Financial Advisors LLC increased its holdings in shares of Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.